Last reviewed 2026-04-22 · How we verify

Rematazolam Besylate

Second Affiliated Hospital of Nanchang University · FDA-approved active Small molecule

Rematazolam Besylate is a Benzodiazepine Small molecule drug developed by Second Affiliated Hospital of Nanchang University. It is currently FDA-approved for Procedural sedation, Acute anxiety and agitation.

Rematazolam besylate is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors in the central nervous system.

Rematazolam besylate is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors in the central nervous system. Used for Procedural sedation, Acute anxiety and agitation.

At a glance

Generic name	Rematazolam Besylate
Sponsor	Second Affiliated Hospital of Nanchang University
Drug class	Benzodiazepine
Target	GABA-A receptor
Modality	Small molecule
Therapeutic area	Neurology / Anesthesia
Phase	FDA-approved

Mechanism of action

As a benzodiazepine, rematazolam besylate potentiates the inhibitory effects of GABA at GABA-A receptors, leading to increased chloride ion influx and neuronal hyperpolarization. This results in sedative, anxiolytic, and anticonvulsant effects. The drug is designed for rapid onset and short duration of action, making it suitable for procedural sedation and acute anxiety management.

Approved indications

Procedural sedation
Acute anxiety and agitation

Common side effects

Sedation
Dizziness
Headache
Respiratory depression

Key clinical trials

Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rematazolam Besylate CI brief — competitive landscape report
Rematazolam Besylate updates RSS · CI watch RSS
Second Affiliated Hospital of Nanchang University portfolio CI

Frequently asked questions about Rematazolam Besylate

What is Rematazolam Besylate?

Rematazolam Besylate is a Benzodiazepine drug developed by Second Affiliated Hospital of Nanchang University, indicated for Procedural sedation, Acute anxiety and agitation.

How does Rematazolam Besylate work?

Rematazolam besylate is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors in the central nervous system.

What is Rematazolam Besylate used for?

Rematazolam Besylate is indicated for Procedural sedation, Acute anxiety and agitation.

Who makes Rematazolam Besylate?

Rematazolam Besylate is developed and marketed by Second Affiliated Hospital of Nanchang University (see full Second Affiliated Hospital of Nanchang University pipeline at /company/second-affiliated-hospital-of-nanchang-university).

What drug class is Rematazolam Besylate in?

Rematazolam Besylate belongs to the Benzodiazepine class. See all Benzodiazepine drugs at /class/benzodiazepine.

What development phase is Rematazolam Besylate in?

Rematazolam Besylate is FDA-approved (marketed).

What are the side effects of Rematazolam Besylate?

Common side effects of Rematazolam Besylate include Sedation, Dizziness, Headache, Respiratory depression.

What does Rematazolam Besylate target?

Rematazolam Besylate targets GABA-A receptor and is a Benzodiazepine.

Drug class: All Benzodiazepine drugs
Target: All drugs targeting GABA-A receptor
Manufacturer: Second Affiliated Hospital of Nanchang University — full pipeline
Therapeutic area: All drugs in Neurology / Anesthesia
Indication: Drugs for Procedural sedation
Indication: Drugs for Acute anxiety and agitation
Compare: Rematazolam Besylate vs similar drugs
Pricing: Rematazolam Besylate cost, discount & access